Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organogenesis Holdings (ORGO) Change in Receivables (2017 - 2025)

Historic Change in Receivables for Organogenesis Holdings (ORGO) over the last 9 years, with Q3 2025 value amounting to $50.7 million.

  • Organogenesis Holdings' Change in Receivables rose 179979.88% to $50.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $73.1 million, marking a year-over-year increase of 36590.85%. This contributed to the annual value of $31.8 million for FY2024, which is 67411.09% up from last year.
  • As of Q3 2025, Organogenesis Holdings' Change in Receivables stood at $50.7 million, which was up 179979.88% from $19.3 million recorded in Q2 2025.
  • In the past 5 years, Organogenesis Holdings' Change in Receivables registered a high of $50.7 million during Q3 2025, and its lowest value of -$7.3 million during Q4 2023.
  • In the last 5 years, Organogenesis Holdings' Change in Receivables had a median value of $5.0 million in 2022 and averaged $6.7 million.
  • Its Change in Receivables has fluctuated over the past 5 years, first tumbled by 16642.34% in 2023, then surged by 179979.88% in 2025.
  • Organogenesis Holdings' Change in Receivables (Quarter) stood at $8.5 million in 2021, then tumbled by 132.21% to -$2.7 million in 2022, then crashed by 166.42% to -$7.3 million in 2023, then surged by 220.6% to $8.8 million in 2024, then surged by 475.74% to $50.7 million in 2025.
  • Its last three reported values are $50.7 million in Q3 2025, $19.3 million for Q2 2025, and -$5.7 million during Q1 2025.